Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.43 |
| ▸ | GRM5 | P41594 | 10/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 3/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21002985 | 0.81 | KDM5A (0.36) | GRM5 | |
| SCHEMBL29899534 | 0.81 | GRM1 (0.45) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL20281623 | 0.78 | PDK4 (0.42) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL20140715 | 0.78 | PDK4 (0.47) | GRM1GRM5PDK4NAMPT | |
| SCHEMBL17672962 | 0.77 | GRM1 (0.39) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL17682563 | 0.77 | HSP90AA1 (0.42) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL25431963 | 0.76 | GRM1 (0.43) | GRM1GRM5PDK4JAK1CDK9 | |
| SCHEMBL31208020 | 0.76 | GRM1 (0.43) | GRM1GRM5PDK4JAK1CDK9 | |
| SCHEMBL28471545 | 0.76 | GRM1 (0.46) | GRM1GRM5PDK4NAMPTCDK9 | |
| SCHEMBL24791836 | 0.75 | GRM1 (0.43) | GRM1GRM5PDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-08 | — | — | US | disclosed |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11434247-B1 | Substituted furanopyrimidine compounds as PDE1 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434247-B1 | Substituted furanopyrimidine compounds as PDE1 inhibitors | PDE4A, PDE5A, PDE3A | GRM1 271/4885GRM5 726/4885PDK4 211/4885 |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | GRM1 271/4885GRM5 726/4885PDK4 211/4885 |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | GRM1 271/4885GRM5 726/4885PDK4 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.